<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Quick-release <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> (<z:chebi fb="0" ids="3181">bromocriptine</z:chebi>-QR), a D2 <z:chebi fb="0" ids="51065">dopamine receptor agonist</z:chebi>, is indicated as a treatment for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 3,095 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were randomized 2:1 to <z:chebi fb="0" ids="3181">bromocriptine</z:chebi>-QR or placebo in conjunction with the patient's usual <z:mp ids='MP_0002055'>diabetes</z:mp> therapy (diet controlled only or up to two antidiabetes medications, including insulin) </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:hpo ids='HP_0000001'>all</z:hpo>-cause-safety end point was the occurrence of any serious adverse event (SAE), with a hazard ratio (HR) noninferiority margin of 1.5 </plain></SENT>
<SENT sid="4" pm="."><plain>In a prespecified analysis, the frequency of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) events defined as a composite of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, coronary revascularization, and hospitalization for <z:mp ids='MP_0006112'>angina</z:mp> or <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> was evaluated using modified intent-to-treat analysis (clinicaltrials.gov, NCT00377676) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In the <z:chebi fb="0" ids="3181">bromocriptine</z:chebi>-QR group, 176 (8.6%) people reported SAEs compared with 98 (9.6%) in the placebo group (HR 1.02 [96% one-sided CI 1.27]) </plain></SENT>
<SENT sid="6" pm="."><plain>Fewer people reported a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> end point in the <z:chebi fb="0" ids="3181">bromocriptine</z:chebi>-QR group versus the placebo group (37 [1.8%] vs. 32 [3.2%], respecively) (HR 0.60 [95% two-sided CI 0.35-0.96]) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002018'>Nausea</z:hpo> was the most commonly reported adverse event in the <z:chebi fb="0" ids="3181">bromocriptine</z:chebi>-QR group </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The frequency of SAEs was comparable between the treatment arms </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with patients in the placebo arm, fewer patients taking <z:chebi fb="0" ids="3181">bromocriptine</z:chebi>-QR experienced a cardiovascular end point </plain></SENT>
</text></document>